Perillyl Alcohol: A Comprehensive Pharmacological and Clinical Review of a Monoterpene's Journey from Oral Disappointment to Intranasal Hope for CNS Malignancies

Introduction: Perillyl Alcohol as an Investigational Oncologic Agent

Perillyl alcohol (POH) is a naturally occurring monoterpene, a C10 isoprenoid synthesized via the mevalonate pathway in a diverse array of plants.[1] It is a key constituent of the essential oils isolated from botanicals such as lavender, peppermint, spearmint, cherries, and celery seeds.[4] For the past three decades, this small molecule has been the subject of intense investigation for its potential anticancer activity, charting a remarkable and instructive course through the landscape of oncologic drug development.[1]

The scientific narrative of perillyl alcohol is one of profound contrasts—a story of initial promise, significant clinical failure, and subsequent rebirth through therapeutic innovation. Based on a wealth of preclinical evidence from animal studies, POH demonstrated compelling antitumor activity, showing an ability to regress pancreatic, mammary, and liver tumors and exhibiting potential as a chemopreventive or chemotherapeutic agent against colon, skin, lung, and prostate cancers.[4] This promising foundation led to a series of clinical trials in the late 1990s and early 2000s. However, these trials, which utilized oral formulations of POH, failed to translate preclinical efficacy into human benefit. The oral route was plagued by poor bioavailability due to extensive first-pass metabolism and dose-limiting gastrointestinal toxicities that proved intolerable for patients, leading to the abandonment of this development pathway.[1]

The trajectory of POH was fundamentally altered by a paradigm shift in its clinical application, pioneered by researchers in Brazil. Recognizing that the molecule itself was active but the delivery method was flawed, they explored intranasal administration as a novel strategy for treating patients with recurrent malignant gliomas.[1] This approach was designed to circumvent the barriers of both hepatic metabolism and the blood-brain barrier (BBB), delivering the compound directly to the central nervous system (CNS). The results were highly encouraging, demonstrating good tolerability and signs of clinical efficacy in a patient population with dismal prognoses.[10] This success revitalized clinical interest in POH, leading to its further development in the United States as NEO100, a highly purified, current Good Manufacturing Practice (cGMP)-produced formulation for intranasal delivery.[15]

The developmental history of perillyl alcohol serves as a critical case study in modern neuro-oncology. It powerfully demonstrates that for certain CNS-targeted therapeutics, the method of delivery is as crucial as the molecular mechanism of the agent itself. The transformation of POH from a failed systemic drug into a promising, targeted therapy for brain malignancies underscores the vital importance of innovative pharmacological strategies in overcoming the unique challenges of treating diseases within the CNS.

Physicochemical Properties, Molecular Identity, and Synthesis

Nomenclature and Chemical Identifiers

Perillyl alcohol is a monocyclic monoterpenoid that exists as a racemic mixture or as one of two enantiomers, (S)-(-) and (R)-(+). Precise identification is critical, as different CAS Registry Numbers are assigned to each form. The user-provided CAS number, 18457-55-1, corresponds specifically to the (S)-(-)-Perillyl Alcohol enantiomer.[18] The racemic mixture is most commonly identified by CAS 536-59-4, while the (R)-(+)-Perillyl alcohol enantiomer is identified by CAS 57717-97-2.[21]

Its formal chemical name is [4-(prop-1-en-2-yl)cyclohex-1-en-1-yl]methanol.[4] It is also known by several synonyms, including Perillol and p-Mentha-1,8-dien-7-ol.[21] The molecule has the chemical formula $C_{10}H_{16}O$ and an average molecular weight of approximately 152.23 g/mol.[4] Key identifiers from major chemical and drug databases include DrugBank ID DB15289, PubChem CID 10819 (for the racemate), and ChEBI ID CHEBI:15420.[2]

Structural representations are defined by the following standard notations:

• InChI (Racemic): InChI=1S/C10H16O/c1-8(2)10-5-3-9(7-11)4-6-10/h3,10-11H,1,4-7H2,2H3 [4]
• InChIKey (Racemic): NDTYTMIUWGWIMO-UHFFFAOYSA-N [4]
• SMILES (Racemic): CC(=C)C1CCC(=CC1)CO [21]

Physical and Chemical Properties

The therapeutic potential and pharmacological behavior of perillyl alcohol are deeply rooted in its physicochemical properties. It presents as a colorless to pale-yellow, oily liquid with a characteristic odor similar to linalool and terpineol.[3] A key feature of POH is its amphipathic nature—it is only slightly soluble in water (approximately 1.9 mg/mL) but is readily soluble in organic solvents like alcohols and oils.[4] This dual character is fundamental to its ability to interact with and cross biological membranes.[1]

Its lipophilicity is quantified by its partition coefficient (logP), with reported values ranging from 1.94 to 3.17, indicating a preference for lipid environments over aqueous ones.[4] This property is critical for its passive diffusion across cell membranes and its potential to penetrate the BBB. Despite its favorable physicochemical profile for absorption—it adheres to both Lipinski's Rule of Five and Veber's Rule, which predict good oral bioavailability—its clinical failure as an oral agent underscores that these rules do not account for metabolic instability, which proved to be the molecule's Achilles' heel.[4] A summary of its key properties is presented in Table 1.

Table 1: Summary of Key Physicochemical and Structural Properties of Perillyl Alcohol

Property	Value	Source(s)
IUPAC Name	[4-(prop-1-en-2-yl)cyclohex-1-en-1-yl]methanol	4
Common Synonyms	Perillyl alcohol, Perillol, p-Mentha-1,8-dien-7-ol	21
CAS Number	536-59-4 (Racemic); 18457-55-1 ((S)-(-)); 57717-97-2 ((R)-(+))	[19, 21, 23]
DrugBank ID	DB15289	25
Molecular Formula	$C_{10}H_{16}O$	[4]
Molecular Weight	Average: 152.237 g/mol; Monoisotopic: 152.120115135 Da	[4, 25]
Physical State	Colorless to pale-yellow oily liquid	3
Water Solubility	1.9 mg/mL	[4, 25]
LogP	1.94 - 3.17	4
pKa (Strongest Acidic)	16.86	[4, 25]
Polar Surface Area	20.23 $Å^2$	[4, 25]
Hydrogen Bond Donors	1	[4, 25]
Hydrogen Bond Acceptors	1	[4, 25]
Rotatable Bonds	2	[4, 25]
Rule of Five Compliance	Yes	[4, 25]

Natural Sources and Synthesis

Perillyl alcohol is widely distributed in nature as a component of the essential oils of plants such as lavender, peppermint, spearmint, sage, cherries, celery seeds, and citrus fruits.[3] It is a naturally occurring metabolite of limonene, a monoterpene that constitutes over 90% of citrus essential oil and is particularly abundant in citrus peels.[10]

While POH can be extracted from natural sources, industrial-scale production relies on chemical synthesis or biosynthesis.

• Synthesis from Limonene: Early methods involved the oxidation of limonene with toxic reagents like selenium dioxide to produce perillaldehyde, which was then reduced to POH. However, this two-step process suffered from low overall yields.[29] More recently, an efficient four-step laboratory synthesis from commercially available limonene oxide has been reported, achieving a 39% overall yield. The key step in this sequence is a palladium(0)-mediated allylic acetate rearrangement.[30]
• Synthesis from Beta-Pinene: Several patented industrial processes start from beta-pinene. One practical method involves the thermal rearrangement of beta-pinene oxide in the presence of a scavenger like sodium carbonate. The resulting crude mixture, rich in perillyl acetate, is then fully acetylated and purified. The final step is the alkaline hydrolysis (saponification) of the perillyl acetate to yield perillyl alcohol, with an overall yield reported to be around 53% based on the starting beta-pinene oxide.[29]
• Biosynthesis: Reflecting a move toward "green chemistry," biotechnological routes have been developed. This has been achieved by genetically engineering Escherichia coli with a heterologous mevalonate pathway, a limonene synthase, and a specific cytochrome P450 monooxygenase that hydroxylates limonene to produce POH.[31] Whole-cell biocatalysis using engineered E. coli expressing enzymes like p-cymene monooxygenase has also been optimized to convert (R)-(+)-limonene to (R)-(+)-perillyl alcohol with high efficiency.[31]

Preclinical Pharmacology: Multifaceted Mechanisms of Anticancer Activity

The initial and enduring interest in perillyl alcohol stems from its broad and potent anticancer activity demonstrated across a wide range of preclinical models, including pancreatic, breast, liver, lung, colon, and brain cancers.[4] POH exerts its effects through pleiotropic mechanisms, impacting multiple, often interconnected, cellular processes that are fundamental to cancer cell survival and proliferation. This multi-targeted action may be a key reason for its observed efficacy in notoriously complex and adaptable malignancies like glioblastoma. While modern drug development often prioritizes highly specific, single-target agents, such drugs can be susceptible to rapid resistance as tumors adapt by rerouting signals through alternative pathways. A pleiotropic agent like POH, by contrast, simultaneously applies pressure to numerous survival networks. This multi-pronged attack may lower the threshold for inducing apoptosis and make it more difficult for the cancer cell to mount an effective resistance, providing a strong mechanistic rationale for its utility.

Modulation of Oncogenic Signaling Pathways

POH has been shown to disrupt several of the most critical signaling cascades that drive cancer growth.

• Inhibition of Protein Prenylation (The Ras Hypothesis): An early and widely studied mechanism involves the inhibition of protein prenylation—the post-translational addition of isoprenoid lipid groups (farnesyl or geranylgeranyl pyrophosphate) to proteins.[8] This modification is essential for the membrane localization and function of many signaling proteins, most notably the small G-proteins of the Ras superfamily.[33] By inhibiting farnesyltransferase and geranylgeranyltransferase, POH and its metabolites were thought to prevent Ras from anchoring to the plasma membrane, thereby blocking its oncogenic signaling.[8] However, subsequent studies raised questions about whether the concentrations of POH achievable in vivo were sufficient to fully displace Ras from the membrane, suggesting this may not be the sole or primary mechanism of action.[8]
• MAPK/ERK Pathway: Downstream of Ras, POH has been shown to inhibit the Mitogen-Activated Protein Kinase (MAPK) pathway by reducing the phosphorylation of Extracellular signal-Regulated Kinase (ERK).[36] In glioblastoma models, POH inhibits this cascade in part by upregulating the expression of Transforming Growth Factor-beta (TGF-β).[38]
• PI3K/Akt/mTOR Pathway: POH targets the PI3K/Akt/mTOR pathway, a central hub for cell growth, survival, and metabolism. It achieves this by attenuating the phosphorylation of Akt, a key survival kinase.[36] Furthermore, POH inhibits the mammalian Target of Rapamycin (mTOR) and its downstream effector, 4E-BP1. De-phosphorylation of 4E-BP1 leads to reduced availability of the eukaryotic initiation factor 4E (eIF4E), which is required for the translation of key proteins involved in cell proliferation and survival.[38]
• Na+/K+-ATPase Inhibition: A distinct mechanism of action is the inhibition of the Na+/K+-ATPase ion pump located in the plasma membrane.[37] Disruption of this pump's function leads to an imbalance in cellular electrolytes, which can trigger pro-apoptotic endoplasmic reticulum (ER) stress, providing another route to induce cell death.[9]

Induction of Cell Cycle Arrest and Apoptosis

POH potently halts cell proliferation and actively triggers programmed cell death in tumor cells, often with a degree of selectivity that spares normal cells.[6]

• Cell Cycle Arrest: POH induces a robust cell cycle arrest in the G1 phase, preventing cells from entering the S phase where DNA is replicated.[3] This is accomplished by modulating the expression of key cell cycle regulators, including the downregulation of proliferative proteins like cyclin D1 and the upregulation of cyclin-dependent kinase (CDK) inhibitors such as p21.[9]
• Induction of Apoptosis: POH is a potent apoptosis inducer that activates multiple components of the cell death machinery.[6]
• Extrinsic (Death Receptor) Pathway: POH upregulates the expression of the FAS death receptor and its cognate ligand (FASL). Binding of FASL to FAS triggers the formation of the death-inducing signaling complex (DISC) and activates the extrinsic apoptotic pathway.[36]
• Caspase Cascade Activation: POH activates both initiator caspases (e.g., caspase-8) and executioner caspases (e.g., caspase-3 and caspase-7). These proteases are the central engines of apoptosis, responsible for cleaving and dismantling key cellular structures and proteins.[36]
• PARP Cleavage: A critical substrate of executioner caspases is Poly (ADP-Ribose) Polymerase 1 (PARP-1), an enzyme involved in DNA repair. POH treatment leads to the caspase-mediated cleavage and inactivation of PARP-1, which both halts DNA repair efforts and serves as a biochemical hallmark of apoptosis.[36]
• Intrinsic (Mitochondrial) Pathway: POH also influences the intrinsic apoptotic pathway by increasing the expression of pro-apoptotic proteins such as Bak.[6]

Impact on the Tumor Microenvironment and Other Activities

Beyond its direct effects on tumor cells, POH also modulates the surrounding microenvironment and exhibits other biological activities.

• Anti-Angiogenesis: Preclinical studies have demonstrated that POH possesses anti-angiogenic properties, interfering with the formation of new blood vessels that are essential for tumor growth and metastasis.[9]
• Modulation of Oxidative Stress and Hypoxia: POH exhibits a nuanced relationship with oxidative stress. It can act as an antioxidant by efficiently scavenging cellular reactive oxygen species (ROS).[39] This activity is mechanistically linked to its ability to suppress tumor adaptation to hypoxia (low oxygen), a common feature of the tumor microenvironment. POH inhibits the expression of Hypoxia-Inducible Factor-1α (HIF-1α), a master regulator of the hypoxic response, by blocking its protein synthesis via the mTOR/4E-BP1 pathway.[38]
• Antimicrobial and Anti-inflammatory Effects: POH also displays broad-spectrum antimicrobial activity against various bacteria (e.g., P. aeruginosa, E. coli) and fungi (e.g., C. albicans).[20] Additionally, it has demonstrated anti-inflammatory properties in animal models of asthma and ulcerative colitis by reducing the expression of inflammatory factors.[3]

Pharmacokinetics (ADME) and the Critical Role of Delivery Route

The clinical development of perillyl alcohol provides a stark illustration of how a drug's absorption, distribution, metabolism, and excretion (ADME) profile—and the strategy used to manage it—can determine its ultimate success or failure. The dramatic difference in clinical outcomes between oral and intranasal POH is rooted entirely in their divergent pharmacokinetics.

The Failure of Oral Administration

The initial clinical trials with POH utilized oral administration, a route that proved to be fundamentally flawed for this molecule.

• Absorption and Bioavailability: Following oral ingestion, POH is rapidly absorbed from the gastrointestinal tract. However, it undergoes extensive first-pass metabolism in the liver, resulting in very poor systemic bioavailability of the parent compound.[33]
• Metabolism: POH is a substrate for cytochrome P450 enzymes, which rapidly and efficiently oxidize it.[10] In humans, the principal circulating metabolites are perillaldehyde, perillic acid (PA), and dihydroperillic acid (DHPA).[9] The parent molecule, POH, has a very short biological half-life (estimated at around 2 hours for its metabolites) and is often difficult to detect in plasma, with peak metabolite levels occurring 2–5 hours post-ingestion.[44]
• Excretion: The polar metabolites are further processed via glucuronidation and are then primarily eliminated through the kidneys into the urine, with a minor fraction excreted in bile.[10] A Phase I study found that only about 9% of the total administered oral dose was recovered in the urine within the first 24 hours, almost entirely as metabolites.[44]
• Clinical Consequence: This pharmacokinetic profile was the direct cause of the oral formulation's clinical failure. To achieve potentially therapeutic systemic concentrations of active metabolites, very large and frequent doses were required.[47] This high dosing regimen led directly to the dose-limiting and poorly tolerated gastrointestinal side effects—including unrelenting nausea, vomiting, and satiety—that caused high rates of patient withdrawal from clinical trials and ultimately led to the cessation of the oral POH program.[10]

The Promise of Intranasal Administration

The shift to intranasal delivery was a strategic maneuver designed to leverage unique anatomical pathways to overcome the pharmacokinetic barriers that doomed the oral route.

• Rationale—Bypassing Barriers: Intranasal administration for CNS delivery is predicated on the ability of certain molecules to bypass two major obstacles: hepatic first-pass metabolism and the blood-brain barrier.[49] The proposed mechanism involves direct nose-to-brain transport along the olfactory and trigeminal nerve pathways, which originate in the nasal mucosa and terminate within the CNS.[34] This route avoids initial passage through the systemic circulation and the liver, theoretically allowing for higher drug concentrations in the brain and cerebrospinal fluid (CSF) with reduced systemic exposure and toxicity.[50]
• Preclinical and Clinical Evidence: This hypothesis is now supported by both animal and human data.
• In a pivotal preclinical study in rats, intranasal POH administration resulted in tenfold higher CSF-to-plasma concentration ratios for the parent drug compared to an equivalent intravascular dose. Moreover, the absolute concentration of the metabolite PA in the CSF was also tenfold higher, providing clear evidence of efficient, direct transport from the nasal cavity to the CNS.[52]
• This finding was definitively confirmed in humans during the NCT02704858 trial. A patient self-administered a dose of intranasal NEO100 on the day of surgery for a recurrent glioblastoma. Subsequent analysis of the resected tumor tissue revealed the presence of both POH and its metabolite, PA.[53] This was a landmark result, providing the first direct proof that intranasal delivery successfully transports the drug to its target tissue within the human brain.[55] Interestingly, while plasma levels of PA were approximately 100-fold higher than POH, the ratio of PA to POH in the tumor tissue was only about 1.4, suggesting a much slower rate of metabolism within the CNS environment compared to the systemic circulation.[55]

The stark contrast between these two delivery routes is summarized in Table 2.

Table 2: Comparative Pharmacokinetic and Clinical Outcomes of Oral vs. Intranasal Perillyl Alcohol

Parameter	Oral Administration	Intranasal Administration
Bioavailability	Very low due to first-pass metabolism	High local (CNS) bioavailability
First-Pass Metabolism	Extensive (hepatic)	Bypassed
Primary Metabolites	Perillic acid (PA), Dihydroperillic acid (DHPA)	PA and DHPA (systemic), but parent POH reaches CNS
Achievable Brain/CSF Concentration	Low; requires very high systemic doses	High; direct nose-to-brain transport demonstrated
Dose-Limiting Toxicity	Intolerable gastrointestinal distress (nausea, vomiting)	Mild, local nasal irritation
Clinical Efficacy in CNS Tumors	Unimpressive; trials abandoned	Promising (PFS/OS benefit in recurrent glioma)

Clinical Development and Efficacy

The clinical history of perillyl alcohol is a tale of two distinct eras: an early period of widespread failure with oral formulations, followed by a modern renaissance driven by intranasal delivery for CNS malignancies.

Early Phase Oral Trials: A Pattern of Disappointment

Following promising preclinical data, a series of Phase I and II clinical trials were initiated in the late 1990s and early 2000s to evaluate oral POH across a range of advanced cancers. The results were uniformly disappointing.

• Refractory Cancers (NCT00002862): A Phase I dose-escalation study was conducted in patients with various refractory solid tumors and lymphomas. The trial successfully identified the maximum tolerated dose and confirmed that the dose-limiting toxicities were gastrointestinal in nature. However, no objective tumor responses were observed; the best outcome was disease stabilization for six months or more in a subset of patients.[44]
• Metastatic Cancers: Phase II trials were conducted in specific cancer types, including metastatic breast cancer (NCT00003219) and androgen-independent metastatic prostate cancer (NCT00003238).[48] While preclinical data had suggested a potential mechanism in prostate cancer via inhibition of the androgen receptor [59], the clinical results were unimpressive.[48] Similar trials in metastatic colorectal and pancreatic cancer (NCT00003769) also failed to demonstrate meaningful clinical benefit.[48]
• Overall Conclusion: The oral POH clinical program was ultimately halted. The therapeutic window proved to be non-existent; the large, multi-gram daily doses required to achieve potentially effective systemic concentrations of metabolites resulted in chronic, unpleasant side effects that led to poor patient compliance and high trial dropout rates.[1]

Intranasal POH (NEO100) for High-Grade Gliomas: A Clinical Renaissance

The reinvention of POH as a neuro-oncology agent began with pioneering clinical work in Brazil, which provided the critical proof-of-concept that intranasal delivery could be both safe and effective.[10] A retrospective analysis of 198 patients with recurrent malignant glioma treated with long-term intranasal POH inhalation found the regimen to be well-tolerated and capable of inducing long-term remission, with 19% of patients surviving for over four years on exclusive POH therapy.[13]

This success laid the groundwork for a formal, FDA-regulated clinical trial in the United States.

• NCT02704858 (Phase I/IIa in Recurrent Glioma): This ongoing trial is evaluating NEO100, a highly purified, cGMP-manufactured formulation of POH, in patients with recurrent or progressive Grade III or IV gliomas.[16]
• Design and Dosing: The study began with a Phase I dose-escalation phase using a standard 3+3 design, followed by a Phase IIa expansion. Patients self-administer NEO100 via a nebulizer and nasal mask four times per day in 28-day cycles.[16]
• Phase I Results: The Phase I portion (n=12) demonstrated an excellent safety profile. The treatment was well-tolerated at all dose levels tested, up to 1152 mg/day, and no severe (Grade 3 or 4) adverse events were reported.[15]
• Efficacy Outcomes: The efficacy signals observed were highly encouraging for this difficult-to-treat patient population. Key results from the Phase I cohort included a progression-free survival at 6 months (PFS-6) of 33%, an overall survival at 12 months (OS-12) of 55%, and a median overall survival (OS) of 15 months.[15] These outcomes compare favorably to historical controls for recurrent glioblastoma.
• The IDH1-Mutant Signal: A particularly striking finding emerged from molecular analysis of the patients' tumors. The therapeutic benefit was significantly more pronounced in patients whose tumors harbored a mutation in the isocitrate dehydrogenase 1 (IDH1) gene. In the Phase I cohort, 4 out of 5 patients (80%) with IDH1-mutant tumors survived for more than 24 months. In contrast, all patients with IDH1-wild type tumors had succumbed to their disease by 18 months.[16] This discovery has been pivotal, transforming POH from a general glioma therapy into a potential precision agent for a genetically defined patient subset. The trial has since been amended to specifically focus on enrolling patients with recurrent Grade III/IV IDH1-mutated gliomas.[54]

Emerging Clinical Applications and Future Trials

The success in glioma has spurred investigation into other challenging CNS malignancies and patient populations. A summary of the ongoing and planned clinical program is presented in Table 3.

Table 3: Summary of Major Clinical Trials of Intranasal Perillyl Alcohol (NEO100) for CNS Malignancies

Trial ID	Phase	Status	Indication	Key Eligibility Criteria	Dosing Regimen	Key Efficacy Results / Endpoints
NCT02704858	1/2a	Recruiting	Recurrent/Progressive Grade III or IV IDH1-mutated Glioma	Radiographically confirmed progression; IDH1 mutation	Intranasal NEO100, 4x daily in 28-day cycles	Phase I (n=12): PFS-6: 33%; OS-12: 55%; Median OS: 15 months. 80% of IDH1-mutant patients survived >24 months.
NCT05023018	2	Recruiting	Residual, Progressive, or Recurrent High-Grade Meningioma (WHO Grade II/III)	Age ≥ 12 years; failed maximal safe resection and radiation therapy	Intranasal NEO100, 4x daily in 28-day cycles	Primary Endpoint: PFS-6. Secondary: OS, radiographic response.
NCT06357377	1	Not yet recruiting	Pediatric Brain Tumors	Patients with aggressive tumors including diffuse midline glioma	Intranasal NEO100; dose-escalation cohorts	Primary Endpoint: Safety, MTD. Secondary: PK, radiographic response.

Safety, Tolerability, and Drug Interactions

The safety profile of perillyl alcohol is defined by a stark dichotomy between its oral and intranasal administration routes, providing a clear lesson on the impact of drug delivery on patient tolerability.

A Tale of Two Routes: Contrasting Safety Profiles

• Oral Administration: The clinical trials of oral POH were consistently hampered by a challenging safety profile dominated by dose-related gastrointestinal toxicity. Patients experienced chronic and unpleasant symptoms, including nausea, vomiting, an unpleasant taste, early satiety, and frequent eructation (belching).[9] While these side effects were typically graded as mild to moderate (Grade 1-2), their persistent and unrelenting nature severely impacted quality of life, leading to poor patient compliance and high rates of withdrawal from the studies.[10] At the highest doses tested, more significant systemic toxicities were observed, including reversible Grade 3 or higher granulocytopenia, hypokalemia (low blood potassium), and stomatitis (inflamed oral mucous membranes).[9]
• Intranasal Administration (NEO100): In sharp contrast, the intranasal delivery of NEO100 has demonstrated an exceptionally favorable safety profile. Across the dose-escalation cohorts of the Phase I trial (NCT02704858), the treatment was remarkably well-tolerated, and no severe (Grade 3 or 4) adverse events related to the drug were reported.[15] The observed adverse events were mild (Grade 1), transient, and localized to the administration site. These included nasal soreness, itching, rhinorrhea (runny nose), and minor skin irritation around the nose where the delivery mask was worn.[13] This excellent tolerability is a crucial advantage, as it permits the long-term, continuous daily administration necessary for managing a persistent and infiltrative disease like glioblastoma.[10]

Drug-Drug Interactions

The DrugBank database catalogues several potential drug-drug interactions for perillyl alcohol, primarily based on theoretical mechanisms or preclinical data.[25]

• Risk of Methemoglobinemia: A significant number of potential interactions involve an increased risk or severity of methemoglobinemia. This condition, where hemoglobin is oxidized and unable to carry oxygen, may be exacerbated when POH is combined with various local anesthetics (e.g., benzocaine, lidocaine, bupivacaine, articaine) and other compounds such as ambroxol, capsaicin, and phenol.[25]
• Risk of Thrombosis: A potential for an increased risk of thrombosis is noted when POH is combined with erythropoiesis-stimulating agents, including erythropoietin, darbepoetin alfa, and peginesatide.[25]
• Risk of Immunosuppression: An interaction with the S1P receptor modulator Etrasimod may increase the risk of immunosuppression.[25]

It is important to note that these are largely predicted interactions. Their clinical relevance, particularly in the context of intranasal administration where systemic drug concentrations are lower than with the oral route, has not been established and is likely minimal. Nevertheless, awareness of these potential interactions is warranted.

Regulatory Landscape and Future Directions

The development of perillyl alcohol is currently concentrated in the United States, where its sponsor, NeOnc Technologies, Inc., has successfully navigated the regulatory pathway to advance its intranasal formulation, NEO100, into mid-stage clinical trials for CNS malignancies.

United States (FDA) Status

Perillyl alcohol is an investigational drug and is not approved by the U.S. Food and Drug Administration (FDA) for any indication.[57] However, the FDA has granted NEO100 several important designations that recognize its potential and are designed to accelerate its development and review process.

• Orphan Drug Designation: Granted on April 18, 2011, for the "Treatment of glioma".[66] This designation provides incentives, including market exclusivity, for the development of treatments for rare diseases affecting fewer than 200,000 people in the U.S.
• Fast Track Designation: Granted for the development of NEO100 in recurrent grade IV glioma.[63] This status is intended to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.
• Rare Pediatric Disease Designation (RPDD): Granted in March 2025 for the treatment of pediatric-type diffuse high-grade gliomas.[68] This designation is for serious or life-threatening diseases primarily affecting individuals aged 18 years or younger. A key benefit is that upon approval of a marketing application, the sponsor may receive a Priority Review Voucher (PRV), which can be used to obtain an expedited six-month review for a future drug application and is a valuable, tradable asset.

European Union (EMA) and Australia (TGA) Status

Currently, the regulatory and clinical development of perillyl alcohol appears to be focused on the U.S. market. A review of the databases of the European Medicines Agency (EMA) and the national registers of its member states reveals no marketing authorization or active public evaluation for perillyl alcohol.[4] Similarly, a search of the Australian Register of Therapeutic Goods (ARTG), maintained by the Therapeutic Goods Administration (TGA), shows no approved therapeutic goods containing perillyl alcohol.[73] This suggests a strategic, US-centric approach by the sponsor, likely aimed at achieving initial FDA approval before pursuing broader global registration.

Future Directions and Next-Generation Derivatives

The immediate future for POH hinges on the outcomes of the ongoing Phase II trials in glioma (NCT02704858) and meningioma (NCT05023018), and the initiation of the planned Phase I pediatric trial (NCT06357377). Positive data from these studies will be essential to support the design and launch of a pivotal Phase III registration trial.

Beyond its use as a monotherapy, a highly promising avenue of research is leveraging POH as a chemical scaffold to create next-generation CNS therapeutics. The ultimate value of POH may extend beyond its intrinsic activity to its function as a drug delivery platform. The primary obstacle in treating brain tumors is the BBB, which prevents most chemotherapeutics from reaching their target. The demonstrated ability of intranasally delivered POH to bypass this barrier can be exploited by chemically conjugating it to other potent, but BBB-impermeable, drugs.

• NEO212: This novel molecule is a first-in-class conjugate of POH and temozolomide (TMZ), the standard-of-care alkylating agent for glioblastoma.[38] The POH moiety acts as a lipophilic "Trojan horse," shuttling the TMZ payload across the BBB more efficiently. Preclinical studies have shown that NEO212 has three times the BBB penetration of TMZ, is up to ten times more potent, and is active against TMZ-resistant tumor cells.[12] This concept transforms POH from a single drug into a platform technology, potentially unlocking a new class of CNS-penetrant therapies by enabling other effective but non-penetrant molecules to reach the brain.

Conclusion and Expert Recommendations

The developmental trajectory of perillyl alcohol is a compelling narrative of scientific perseverance and pharmacological ingenuity. Initially dismissed as a clinical failure due to the untenable toxicity and poor bioavailability of its oral formulation, POH has been successfully repurposed through a fundamental shift in its delivery strategy. The adoption of intranasal administration has transformed it from a systemically toxic agent with little efficacy into a well-tolerated, targeted therapy that shows significant promise for treating CNS malignancies. This journey underscores a crucial lesson in drug development: for diseases protected by formidable biological barriers like the BBB, the innovation of a delivery system can be as transformative as the discovery of a novel molecular mechanism.

Based on the available evidence, intranasal perillyl alcohol (NEO100) represents one of the most novel and promising therapeutic approaches currently in clinical development for recurrent high-grade gliomas. Its exceptional safety profile, which permits long-term daily administration, combined with its non-invasive, at-home delivery method, offers a significant quality-of-life advantage over conventional cytotoxic therapies. The strong efficacy signal observed, particularly the durable survival benefit in patients with IDH1-mutant tumors, positions NEO100 as a potential breakthrough for a genetically defined subset of glioma patients with limited treatment options.

To realize the full potential of this agent, the following future research and development steps are recommended:

1. Pivotal Clinical Trials: The highest priority is the initiation of a well-designed, randomized, controlled Phase III trial to definitively establish the efficacy of intranasal NEO100 compared to the current standard of care in patients with recurrent, IDH1-mutant high-grade gliomas.
2. Mechanistic Investigation of IDH1-Sensitivity: A critical area for basic and translational research is to elucidate the biological mechanism responsible for the heightened sensitivity of IDH1-mutant tumors to POH. Understanding this interaction could reveal new biomarkers, refine patient selection, and uncover novel therapeutic vulnerabilities.
3. Optimization of Delivery and Formulation: Continued research into the precise nose-to-brain transport pathways and the exploration of advanced formulations, such as nanostructured lipid carriers, could further enhance CNS drug concentrations, potentially improving efficacy or reducing dosing frequency.[33]
4. Evaluation of Combination Therapies: Given its excellent safety profile, NEO100 is an ideal candidate for combination studies. Trials evaluating its use alongside standard-of-care radiation and temozolomide, as well as with other targeted agents or immunotherapies, should be pursued.
5. Development of the POH Conjugate Platform: The highly promising preclinical data for the POH-TMZ conjugate, NEO212, strongly validates the concept of using POH as a chemical scaffold to enhance CNS delivery. This "Trojan horse" strategy should be expanded to other potent anticancer agents that are currently limited by their inability to cross the BBB, representing a potentially revolutionary platform for neuro-oncology drug development.

Works cited

1. The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers - ResearchGate, accessed October 31, 2025, https://www.researchgate.net/publication/357091581_The_Monoterpenoid_Perillyl_Alcohol_Anticancer_Agent_and_Medium_to_Overcome_Biological_Barriers
2. CHEBI:15420 - perillyl alcohol - EMBL-EBI, accessed October 31, 2025, https://www.ebi.ac.uk/chebi/chebiOntology.do?chebiId=CHEBI:15420
3. Perillyl alcohol | 18457-55-1 - MedKoo Biosciences, accessed October 31, 2025, https://www.medkoo.com/products/8767
4. Metabolite Perillyl alcohol | DrugBank Online, accessed October 31, 2025, https://go.drugbank.com/metabolites/DBMET01188
5. Showing metabocard for Perillyl alcohol (HMDB0003634) - Human Metabolome Database, accessed October 31, 2025, https://www.hmdb.ca/metabolites/HMDB0003634
6. Perillyl Alcohol: Applications in Oncology - Alternative Medicine Review, accessed October 31, 2025, https://altmedrev.com/wp-content/uploads/2019/02/v3-6-448.pdf
7. Perillyl Alcohol | Memorial Sloan Kettering Cancer Center, accessed October 31, 2025, https://www.mskcc.org/pdf/cancer-care/patient-education/herbs/perillyl-alcohol
8. Perillyl Alcohol as a Chemopreventive Agent in N-Nitrosomethylbenzylamine-induced Rat Esophageal Tumorigenesis1 - AACR Journals, accessed October 31, 2025, https://aacrjournals.org/cancerres/article/63/10/2399/509910/Perillyl-Alcohol-as-a-Chemopreventive-Agent-in-N
9. Perillyl Alcohol - Memorial Sloan Kettering Cancer Center, accessed October 31, 2025, https://www.mskcc.org/cancer-care/integrative-medicine/herbs/perillyl-alcohol
10. Review Article Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy, accessed October 31, 2025, https://e-century.us/files/ajcr/5/5/ajcr0007197.pdf
11. Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy - ResearchGate, accessed October 31, 2025, https://www.researchgate.net/publication/280103677_Preclinical_development_and_clinical_use_of_perillyl_alcohol_for_chemoprevention_and_cancer_therapy
12. Abstract B77: Perillyl alcohol derivatives as anticancer agents - AACR Journals, accessed October 31, 2025, https://aacrjournals.org/clincancerres/article/24/1_Supplement/B77/198419/Abstract-B77-Perillyl-alcohol-derivatives-as
13. Long-term Outcome in Patients with Recurrent Malignant Glioma Treated with Perillyl Alcohol Inhalation | Anticancer Research, accessed October 31, 2025, https://ar.iiarjournals.org/content/33/12/5625
14. Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development - PMC - PubMed Central, accessed October 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6321279/
15. NEO100 Human Trial In Adult Patients With Recurrent Glioblastoma - NeOnc Technologies, accessed October 31, 2025, https://neonc.com/neo100-human-trial-in-adult-patients-with-recurrent-glioblastoma/
16. Phase i trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma - Providence, accessed October 31, 2025, https://providence.elsevierpure.com/en/publications/phase-i-trial-of-intranasal-neo100-highly-purified-perillyl-alcoh
17. Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma - PubMed Central, accessed October 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7879254/
18. (-)-Perillyl Alcohol | CAS 18457-55-1 | SCBT - Santa Cruz Biotechnology, accessed October 31, 2025, https://www.scbt.com/p/perillyl-alcohol-18457-55-1
19. (-)-Perillyl alcohol - CAS Common Chemistry, accessed October 31, 2025, https://commonchemistry.cas.org/detail?cas_rn=18457-55-1
20. (-)-PERILLYL ALCOHOL | 18457-55-1 - ChemicalBook, accessed October 31, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9490602.htm
21. Perillyl Alcohol | C10H16O | CID 10819 - PubChem, accessed October 31, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/10819
22. p-Mentha-1,8-dien-7-ol - the NIST WebBook, accessed October 31, 2025, https://webbook.nist.gov/cgi/cbook.cgi?ID=C536594&Mask=200
23. (+)-Perillyl alcohol | C10H16O | CID 11788398 - PubChem, accessed October 31, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/4R_-4-prop-1-en-2-ylcyclohexen-1-yl_methanol
24. www.selleckchem.com, accessed October 31, 2025, https://www.selleckchem.com/products/perillyl-alcohol.html
25. Perillyl alcohol: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed October 31, 2025, https://go.drugbank.com/drugs/DB15289
26. Perillyl Alcohol: Health Benefits, Side Effects, Uses, Dose & Precautions - RxList, accessed October 31, 2025, https://www.rxlist.com/supplements/perillyl_alcohol.htm
27. Perillyl Alcohol (Monoterpene Alcohol), Limonene - PubMed, accessed October 31, 2025, https://pubmed.ncbi.nlm.nih.gov/27102697/
28. (PDF) Perillyl Alcohol (Monoterpene Alcohol), Limonene, accessed October 31, 2025, https://www.researchgate.net/publication/284829344_Perillyl_Alcohol_Monoterpene_Alcohol_Limonene
29. US5994598A - Method of preparing perillyl alcohol and perillyl ..., accessed October 31, 2025, https://patents.google.com/patent/US5994598A/en
30. Synthesis of (+)-perillyl alcohol from (+)-limonene - Sci-Hub, accessed October 31, 2025, https://2024.sci-hub.se/2360/0e7759db5f89ebb32d01dda86179abae/geoghegan2014.pdf
31. Efficient Synthesis of (R)-(+)-Perillyl Alcohol From (R)-(+)-Limonene Using Engineered Escherichia coli Whole Cell Biocatalyst - Frontiers, accessed October 31, 2025, https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2022.900800/full
32. Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy - PMC - PubMed Central, accessed October 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4497427/
33. Enhancing Oral Bioavailability and Brain Biodistribution of Perillyl Alcohol Using Nanostructured Lipid Carriers - MDPI, accessed October 31, 2025, https://www.mdpi.com/1424-8247/16/8/1055
34. Exploratory study of monoterpene perillyl alcohol intranasal administration in patients with recurrent gliomas | Journal of Clinical Oncology - ASCO Publications, accessed October 31, 2025, https://ascopubs.org/doi/10.1200/jco.2008.26.15_suppl.14650
35. Study Details | NCT05023018 | NEO100 and High-Grade ..., accessed October 31, 2025, https://clinicaltrials.gov/study/NCT05023018
36. Metabolic and Regulatory Pathways Involved in the Anticancer Activity of Perillyl Alcohol: A Scoping Review of In Vitro Studies - MDPI, accessed October 31, 2025, https://www.mdpi.com/2072-6694/16/23/4003
37. Metabolic and Regulatory Pathways Involved in the Anticancer Activity of Perillyl Alcohol: A Scoping Review of In Vitro Studies - PMC, accessed October 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11640718/
38. Mechanisms of action of perillyl alcohol (POH) in cancer cells,... - ResearchGate, accessed October 31, 2025, https://www.researchgate.net/figure/Mechanisms-of-action-of-perillyl-alcohol-POH-in-cancer-cells-according-to-the-in-vitro_fig2_386251614
39. Perillyl Alcohol Efficiently Scavenges Activity of Cellular ROS and Inhibits the Translational Expression of Hypoxia-Inducible factor-1α via mTOR/4E-BP1 Signaling Pathways - PubMed, accessed October 31, 2025, https://pubmed.ncbi.nlm.nih.gov/27394002/
40. Perillyl alcohol | Anticancer Agent | MedChemExpress, accessed October 31, 2025, https://www.medchemexpress.com/perillyl-alcohol.html
41. Perillyl alcohol, a pleiotropic natural compound suitable for brain tumor therapy, targets free radicals - PubMed, accessed October 31, 2025, https://pubmed.ncbi.nlm.nih.gov/28314870/
42. (−)-Perillyl Alcohol - Cayman Chemical, accessed October 31, 2025, https://www.caymanchem.com/product/21860/
43. Perillyl alcohol and its synthetic derivatives: the rising of a novel class of selective and potent antitumoral compounds - ResearchGate, accessed October 31, 2025, https://www.researchgate.net/publication/359449441_Perillyl_alcohol_and_its_synthetic_derivatives_the_rising_of_a_novel_class_of_selective_and_potent_antitumoral_compounds
44. Phase I clinical trial of perillyl alcohol administered daily, accessed October 31, 2025, https://pubmed.ncbi.nlm.nih.gov/9607573/
45. Pharmacokinetic properties of the temozolomide perillyl alcohol conjugate (NEO212) in mice | Neuro-Oncology Advances | Oxford Academic, accessed October 31, 2025, https://academic.oup.com/noa/article/2/1/vdaa160/5995596
46. Phase I clinical trial of perillyl alcohol administered daily - MD Anderson Cancer Center, accessed October 31, 2025, https://mdanderson.elsevierpure.com/en/publications/phase-i-clinical-trial-of-perillyl-alcohol-administered-daily
47. Pharmacokinetics of active drug metabolites after oral administration of perillyl alcohol, an investigational antineoplastic agent, to the dog - PubMed, accessed October 31, 2025, https://pubmed.ncbi.nlm.nih.gov/7587953/
48. Incorporation of Perillyl Alcohol into Lipid-Based Nanocarriers Enhances the Antiproliferative Activity in Malignant Glioma Cells - MDPI, accessed October 31, 2025, https://www.mdpi.com/2227-9059/11/10/2771
49. Intranasal Perillyl Alcohol for Glioma Therapy: Molecular ... - MDPI, accessed October 31, 2025, https://www.mdpi.com/1422-0067/19/12/3905
50. Intranasal Terpene Treatment for Glioblastoma: the Neuro-Oncological Potential of Perillyl Alcohol, accessed October 31, 2025, https://openaccess.biruni.edu.tr/xmlui/bitstream/handle/20.500.12445/3702/Intranasal%20Terpene%20Treatment%20for%20Glioblastoma%20the%20Neuro-Oncological.pdf?sequence=1&isAllowed=y
51. Perillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain Metastases - MDPI, accessed October 31, 2025, https://www.mdpi.com/1422-0067/17/9/1463
52. (PDF) Intranasal administration of the chemotherapeutic perillyl ..., accessed October 31, 2025, https://www.researchgate.net/publication/350161383_Intranasal_administration_of_the_chemotherapeutic_perillyl_alcohol_results_in_selective_delivery_to_the_cerebrospinal_fluid_in_rats
53. Study Details | NCT02704858 | Safety and Efficacy Study in ..., accessed October 31, 2025, https://clinicaltrials.gov/study/NCT02704858
54. NCT02704858 | Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | ClinicalTrials.gov, accessed October 31, 2025, https://www.clinicaltrials.gov/study/NCT02704858
55. Postsurgical Biopsy Shows Viability of NEO100 Intranasal Delivery - NeOnc Technologies, accessed October 31, 2025, https://neonc.com/postsurgical-biopsy-shows-viability-of-neo100-intranasal-delivery/
56. Study Details | NCT00002862 | Perillyl Alcohol in Treating Patients With Refractory Cancer | ClinicalTrials.gov, accessed October 31, 2025, https://clinicaltrials.gov/study/NCT00002862
57. Perillyl alcohol | MedPath, accessed October 31, 2025, https://trial.medpath.com/drug/f4fde5d586d92595/perillyl-alcohol
58. Study Details | NCT00003238 | Perillyl Alcohol in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | ClinicalTrials.gov, accessed October 31, 2025, https://www.clinicaltrials.gov/study/NCT00003238
59. Perillyl alcohol inhibits the expression and function of the androgen receptor in human prostate cancer cells - PubMed, accessed October 31, 2025, https://pubmed.ncbi.nlm.nih.gov/16029925/
60. Perillyl Alcohol for Glioblastoma - Clinical Trials, accessed October 31, 2025, https://www.withpower.com/trial/phase-2-glioblastoma-3-2016-4b86c
61. Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma - PubMed, accessed October 31, 2025, https://pubmed.ncbi.nlm.nih.gov/33604574/
62. (PDF) Phase I trial of intranasal NEO100, highly purified perillyl ..., accessed October 31, 2025, https://www.researchgate.net/publication/349284980_Phase_I_trial_of_intranasal_NEO100_highly_purified_perillyl_alcohol_in_adult_patients_with_recurrent_glioblastoma
63. FDA allows expansion of Phase 2a trial NeOnc's NEO100 intranasal perillyl alcohol to include additional type of brain tumor - OINDP News, accessed October 31, 2025, https://www.oindpnews.com/2024/07/fda-allows-expansion-of-phase-2a-trial-neoncs-neo100-intranasal-perillyl-alcohol-to-include-additional-type-of-brain-tumor/
64. NeOnc Technologies - A New Clinical Trial - Anova, accessed October 31, 2025, https://anovaevidence.com/neonc-technologies-a-new-clinical-trial/
65. Access To Better Care For Every Patient - South Sound Care Foundation, accessed October 31, 2025, https://www.southsoundcarefoundation.org/blog/you-give-patients-hope
66. Search Orphan Drug Designations and Approvals - accessdata.fda ..., accessed October 31, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=340411
67. Abstract CT064: Intranasal brain delivery using NEO100 for recurrent glioblastoma, accessed October 31, 2025, https://aacrjournals.org/cancerres/article/79/13_Supplement/CT064/637769/Abstract-CT064-Intranasal-brain-delivery-using
68. Oncology Drugs Granted FDA Designations in March 2025, accessed October 31, 2025, https://www.oncologynewscentral.com/drug/oncology-drugs-granted-fda-designations-in-march-2025
69. Neo100: Rare Pediatric Disease Designation for High-Grade Gliomas, accessed October 31, 2025, https://www.clinicaltrialvanguard.com/news/neo100-rare-pediatric-disease-designation-for-high-grade-gliomas/
70. FDA Grants Rare Pediatric Designation to Treatment With NEO100 in Brain Cancer | CURE, accessed October 31, 2025, https://www.curetoday.com/view/fda-grants-rare-pediatric-designation-to-treatment-with-neo100-in-brain-cancer
71. Medicines for human use under evaluation | European Medicines Agency (EMA), accessed October 31, 2025, https://www.ema.europa.eu/en/medicines/medicines-human-use-under-evaluation
72. Medicines | European Medicines Agency (EMA), accessed October 31, 2025, https://www.ema.europa.eu/en/medicines
73. Australian Register of Therapeutic Goods (ARTG), accessed October 31, 2025, https://www.tga.gov.au/products/australian-register-therapeutic-goods-artg
74. Therapeutic Goods Administration (TGA) | Australian Government Department of Health, Disability and Ageing, accessed October 31, 2025, https://www.tga.gov.au/
75. Australian Register of Therapeutic Goods (ARTG) | Therapeutic ..., accessed October 31, 2025, https://www.tga.gov.au/artg
76. Plasma concentration–time curves of perillyl acid (PA) obtained after... - ResearchGate, accessed October 31, 2025, https://www.researchgate.net/figure/Plasma-concentration-time-curves-of-perillyl-acid-PA-obtained-after-single-oral_fig5_372641190